Target Name: RFC4
NCBI ID: G5984
Review Report on RFC4 Target / Biomarker Content of Review Report on RFC4 Target / Biomarker
RFC4
Other Name(s): activator 1 37 kDa subunit | RFC37 | RFC 37 kDa subunit | Replication factor C subunit 4, transcript variant 1 | MGC27291 | replication factor C 37 kDa subunit | A1 | replication factor C (activator 1) 4, 37kDa | RF-C 37 kDa subunit | A1 37 kDa subunit | Activator 1 subunit 4 | Replication factor C (activator 1) 4 (37kD) | replication factor C subunit 4 | Replication factor C subunit 4, transcript variant 2 | Activator 1 37 kDa subunit | RFC4 variant 2 | RFC4_HUMAN | activator 1 subunit 4 | RFC4 variant 1 | Replication factor C 37 kDa subunit | Replication factor C subunit 4

RFC4: A Promising Drug Target and Biomarker for ALZHEIMER'S DISEASE

Introduction

Alzheimer's disease is a debilitating and fatal neurological disorder that affects millions of people worldwide. It is characterized by the progressive accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain, leading to a range of symptoms, including memory loss, cognitive decline, and behavioral changes. Currently, there is no cure for Alzheimer's disease, and drug treatments are only able to slow down the progression of the disease and provide temporary relief from symptoms. As a result, there is a high demand for new and effective treatments that can prevent or reverse the effects of Alzheimer's disease.

RFC4 is a protein that is expressed in the brain and has been shown to be involved in the development and progression of Alzheimer's disease. In this article, we will discuss the potential implications of RFC4 as a drug target and biomarker for Alzheimer's disease.

The RFC4 Protein

RFC4 is a heat shock protein (HSP) that is expressed in the brain and has been shown to be involved in a number of important cellular processes. It is a 37 kDa subunit and is composed of two main domains: an N-terminal alpha- helix and a C-terminal domain that contains a conserved secretory domain and a transmembrane region.

The N-terminal alpha-helix is 鈥嬧?媡he primary structural domain of RFC4 and is responsible for the protein's stability and localization to the brain. The C-terminal domain is the region that contains the conserved secretory domain and is involved in the formation of a hydrophobic core that is thought to play a role in the protein's stability and interactions with other cellular components.

Several studies have shown that RFC4 is involved in the development and progression of Alzheimer's disease. For example, researchers have found that RFC4 levels are decreased in the brains of people with Alzheimer's disease and that inhibiting RFC4 using drugs or RNA interference can protect against the development of the disease in animal models.

In addition to its involvement in the development of Alzheimer's disease, RFC4 has also been shown to be involved in the progression of several other neurodegenerative diseases. For example, studies have shown that RFC4 is involved in the development of Parkinson's disease and that inhibiting RFC4 using drugs or RNA interference can protect against the progression of the disease in animal models.

Drug Targeting

Drug targeting of RFC4 is a promising approach to treating Alzheimer's disease and other neurodegenerative diseases. By targeting RFC4 with small molecules or antibodies, researchers can reduce the production of beta-amyloid plaques and neurofibrillary tangles, which are thought to be the primary causes of Alzheimer's disease.

One of the challenges in drug targeting of RFC4 is the protein's high stability and the fact that it is expressed in a variety of cellular types, including neurons and glial cells. However, researchers have shown that it is possible to target RFC4 specifically by using antibodies that recognize the protein's conserved carboxylic acid residues.

Another approach to drug targeting of RFC4 is the use of small molecules that can modulate the activity of the protein. For example, researchers have shown that inhibitors of the protein's N-terminal alpha-helix can protect against the development of Alzheimer's disease in animal models.

Biomarker Potential

RFC4 has also been shown to be a potential biomarker for Alzheimer's disease. The protein is expressed in the brain and is not expressed in other tissues, which makes it a promising target for diagnostic tests.

Research has shown that RFC4 levels are decreased in the brains of people with Alzheimer's disease, which suggests that it may be a useful biomarker for the disease. In addition, the fact that RFC4 is involved in the development and progression of Alzheimer's disease suggests that it may also be a useful biomarker for other neurodegenerative diseases.

Conclusion

In conclusion, RFC4 is a protein that is involved in the development and progression of Alzheimer's disease. Its high stability and the fact that it is expressed in a variety of cellular types make it a promising target for drug targeting. In addition, RFC4 has also has been shown to be a potential biomarker for the disease. Further research is needed to fully understand the role of RFC4 in the development and progression of Alzheimer's disease and to develop effective treatments.

Protein Name: Replication Factor C Subunit 4

Functions: The elongation of primed DNA templates by DNA polymerase delta and epsilon requires the action of the accessory proteins proliferating cell nuclear antigen (PCNA) and activator 1. This subunit may be involved in the elongation of the multiprimed DNA template

The "RFC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RFC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RFC5 | RFESD | RFESDP1 | RFFL | RFK | RFLNA | RFLNB | RFNG | RFPL1 | RFPL1S | RFPL2 | RFPL3 | RFPL3S | RFPL4A | RFPL4AL1 | RFPL4B | RFT1 | RFTN1 | RFTN2 | RFWD3 | RFX complex | RFX1 | RFX2 | RFX3 | RFX3-DT | RFX4 | RFX5 | RFX5-AS1 | RFX6 | RFX7 | RFX8 | RFXANK | RFXAP | RGCC | RGL1 | RGL2 | RGL3 | RGL4 | RGMA | RGMB | RGMB-AS1 | RGN | RGP1 | RGPD1 | RGPD2 | RGPD3 | RGPD4 | RGPD4-AS1 | RGPD5 | RGPD6 | RGPD8 | RGR | RGS1 | RGS10 | RGS11 | RGS12 | RGS13 | RGS14 | RGS16 | RGS17 | RGS18 | RGS19 | RGS2 | RGS20 | RGS21 | RGS22 | RGS3 | RGS4 | RGS5 | RGS6 | RGS7 | RGS7BP | RGS8 | RGS9 | RGS9BP | RGSL1 | RHAG | RHBDD1 | RHBDD2 | RHBDD3 | RHBDF1 | RHBDF2 | RHBDL1 | RHBDL2 | RHBDL3 | RHBG | RHCE | RHCG | RHD | RHEB | RHEBL1 | RHEBP1 | RHEX | RHNO1 | RHO | Rho GTPase | Rho kinase (ROCK) | RHOA | RHOB | RHOBTB1